Stockreport

Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria ...

Alexion Pharmaceuticals, Inc  (ALXN) 
Last alexion pharmaceuticals, inc earnings: 1/30 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.alexion.com/investor-relations
PDF -- ALXN1210 Achieved Non-Inferiority to Soliris® (Eculizumab) on Co-Primary Endpoints of Transfusion Avoidance and Lactate Dehydrogenase Normalization, a [Read more]